OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

ok thats fair enough about this OXB thread
i'm off.
agree with you.let others decide
regards
jkd
edit & ps you are the red herring man. what was the original point of these posts?
seems a red herring has intervened or rather been introduced by you on the last post just to mudddy the waters maybe.

t
additionally, would you like me to now tear all your posts to pieces? including the last one bit by bit?
as you tried and failed to do so about my previous posts?
thank you for your request for me to not require to respond. i do understand.for your own sake please do stop digging. i will throw you a rope at some stage.what you use it for is up to you.
regards to you
jkd

Jkdso I am a red herring now?.love you you aint half a pilchard grandad

Anywayhasnt the 20mil got to add a penny or so to the SP?the price took a hit with the dilutionbut the cash is in the bank!any views?

Yes my allocation has not yet arrived but paid for 30 Dec. Thought they would arrive 10 Jan - any views or news

havent got my allocation yet either

My broker tells me that they will arrive into my acct to-day. They are looking into reason for delay.

allocation has arrived now

Good to read the Kingsman family has bought 2m shares, admitidly this buy is at a massive discount to the selling price (39p was it?) a few years ago. At that time it looked sttrange, just before an AGM, but the Co PR machine was well polished and no-one worried...too much.

Nice to think sp might reach those old levels - - -
About time; I've been in since 1999....Grief!

Me too and my enlarged prostate !!

my post 1352 edited with a small addition of 4 words today.
regards
jkd

Jkdground breaking news!

http://www.oxfordbiomedica.co.uk/userfiles/file/pdfs/OBM0111JPM.pdf

Market chatter suggests gene-therapy company Oxford BioMedica (OXB)
is very close to closing a deal to purchase a UK manufacturing facility so it can establish in-house drug production. Buy ahead of the deal being confirmed. Oxford wants its own capacity as it has five other products in clinical development, including a cancer vaccine, Trovax, in Phase II trials. (CM)
Shares says: Speculative Buy at 5.5p

I read that rumour too, (was it you?), but I'm not convinced, unless there is a facility on the cheap.... for they need the Rights money and would have have to have told subscribers/shareholders what they were doing...as that was a while ago (yep!) I think this cash is for working capital...that was what we were told...(anyone?).

Still, often wrong, it would make sense to buy a small Bio-dev.Co. that needed their contacts. Whereas I don't think OXB needs a manufacturing facility - I understood they had some Trovax made a while back and this is still in the fridge. Trials-volume req'd isn't enough to start a production. However, if they can secure a bread-n-butter product, that changes everything.
+ I bought a few more at these lows....but I'm wary we've been seeing lows . . . . . . for rather too long.

HangonI wrote to the company some time ago concerning the manufacturing facilityalong with some other questions

This is part of the reply I received from Lara


"Dear *******


Regarding the manufacturing point you have raised below, we have an exclusive option to acquire a UK-based manufacturing facility at a fraction of the cost of a new-build. We currently have one Phase I/II product, ProSavin, which utilises our EIAV-based LentiVector technology platform (EIAV stands for our equine infectious anemia virus which we use to deliver the genes), however we have four LentiVector-based ocular products, partnered with sanofi-aventis, moving into clinical development over the next 18 months. This moves us from one LentiVector-based programme to five clinically active programmes.

We estimate that it will take about 12 months to bring the manufacturing unit on-stream, but thereafter, based on present plans, the amount of clinical-grade material that our development programmes will require could make the manufacturing unit cost-effective. With five LentiVector products moving from Ph I/II through to Ph II, Ph III and the market, we plan to support our five programmes with control of supply and we would eventually also have the opportunity to be the preferred supplier for our commercial partners.

I hope this provides some clarity.

Best wishes,
Lara"

I now believe OXB are developing the business on privileged information and assurances from partnersthe 18.4ml netwill fund ProSavininvest in manufacturing infrastructure for the LentiVector programmesstrengthen the balance sheetwhich will give OXB a stronger negotiating position for partnering dealsand take us way past the first catalysts associated with the ocular assetsthere is also double digit million dollar milestone paymentswhen Sanofi exercise one or more of the ocular programmesall in all hangonwe now look pretty damn strong

kiss of death!

We have had all the bad news pricedI will be very surprised if the SP is not considerably higher come this date!

Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), today announces that it will be releasing its preliminary results for the twelve months ended 31 December 2010 on Wednesday 2 March 2011.
An analyst briefing will be held at 9:30am GMT on Wednesday 2 March 2011 at the offices of M:Communications, CityPoint, 1 Ropemaker Street, London, EC2Y 9AW.
Simultaneously to the analyst briefing at 9:30am GMT, there will be a live audio webcast of the presentation. To connect to the webcast facility, please visit the Company's website: www.oxfordbiomedica.co.uk approximately 10 minutes (9:20am GMT) before the start of the briefing. A replay will be made available shortly after the presentation.

If you read between the lines OXBs statement on the 22nd December 2010 looks pretty bullishfast track 5x dosethe start of 5x dose treatment is timed perfectly with the preliminary results in MarchDMC approval to open the second site in the UK at Addenbrookesa Phase II trial of ProSavin could be initiated in the EU/US in 2012 and planning is underway for this stage of the development programmeand all around the very badly timed fundraising?Looks fairly confident action to me!

The study's independent Data Monitoring Committee (DMC) has reviewed the data and supports the Company's proposal to proceed to a 5x dose, facilitated by the enhanced administration technique, in a six-patient cohort. Importantly, the 5x human dose is the allometrically-scaled equivalent (i.e. a dose that is scaled for the difference in brain size between humans and the pre-clinical model) to the highly efficacious pre-clinical dose published in Jarraya et al. Sci Transl Med. 2009 Oct 14;1(2). The DMC also gave its approval to open the second site in the UK at Addenbrookes Hospital, Cambridge, with Dr Roger Barker as Principal Investigator, which will recruit some of the six patients into the 5x dose cohort.

Oxford BioMedica plans to initiate treatment of the 5x dose cohort in Q1 2011. To date, nine patients have been treated at the Henri Mondor Hospital, Paris, with Professor Sthane Palfi as Principal Investigator. The first patient in the 5x dose cohort will be treated in Paris, one month after which subsequent patients can be treated in parallel at both sites which is expected to increase the rate of recruitment and treatment. Results from the first three patients in the 5x dose cohort are expected in mid-2011. Depending on the efficacy seen with the 5x dose, a Phase II trial of ProSavin could be initiated in the EU/US in 2012 and planning is underway for this stage of the development programme.

http://clinicaltrials.gov/ct2/show/NCT00627588?term=prosavin&rank=1

ProSavin still at least 3 years away from production, assuming it gets through Phase II and III.

OXB will either have been taken over by then or have returned to the market for additional funds many times over. Very rarely do tiny Bios ever progress a drug from inception to the shelves.

On occasion the market gets excited about the possibilities of a new drug with a likewise reaction to the SP. AZM were a good example, but still ended up in administration.

Blimey - didn't realise this lot were still around.